Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

WZ, Zhong; KN, Chen; C, Chen; CD, Gu; J, Wang; XN, Yang; WM, Mao; Q, Wang; GB, Qiao; Y, Cheng; L, Xu; CL, Wang; MW, Chen; X, Kang; W, Yan; HH, Yan; RQ, Liao; JJ, Yang; XC, Zhang; Q, Zhou; YL, Wu

doi:10.1200/jco.19.00075

Public

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

Shared by NobleBlocks on Jun 13, 2019 • 12:00 AM UTC

Authors:

Zhong WZ

Chen KN

Chen C

Abstract

Purpose To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation-positive non-small-cell lung cancer.Patients and methods This was a multicenter (17 centers in China), open-label, phase II, random...

Discussions